Sunshine Biopharma (SBFM) announced that its wholly owned Canadian subsidiary, Nora Pharma, has acquired the rights to two gastrointestinal ...

Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently ...

Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently recording ...

This and the forthcoming drug are part of Sunshine Biopharma’s strategy to penetrate the chronic idiopathic constipation market, which is part of the larger gastrointestinal market with annual ...

This and the forthcoming drug are part of Sunshine Biopharma’s strategy to penetrate the chronic idiopathic constipation market, which is part of the larger gastrointestinal market with annual sales ...

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help ...

Both Prucalopride and the second drug Sunshine Biopharma is planning to launch by year end are in the chronic idiopathic constipation submarket of the total gastrointestinal market currently ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...